Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T61989 |
CB1R antagonist 1
|
Cannabinoid Receptor | GPCR/G Protein |
CB1R antagonist 1是一种有效的 CB1R 拮抗剂,可用于研究与神经系统相关的疾病。 | |||
T5996 |
CB1-IN-1
DBPR211,1-(2,4-二氯苯基)-N-1-哌啶基-4-[[(1-吡咯烷基磺酰基)氨基]甲基]-5-[5-[2-[4-(三氟甲基)苯基]乙炔基]-2-噻吩基]-1H-吡唑-3-甲酰胺 |
Cannabinoid Receptor | GPCR/G Protein |
CB1-IN-1 (DBPR211) 是新型的外周大麻素-1受体 (CB1R) 拮抗剂,作用于CB1R (EC50 = 3 nM) 和 CB2R 的Ki 分别为0.3 nM 和 21 nM。 | |||
T39074 |
(Rac)-Zevaquenabant
(Rac)-MRI-1867,(Rac)-Zevaquenabant |
||
(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a potent and selective antagonist of the cannabinoid receptor type 1 (CB1R) and inducible nitric oxide synthase (iNOS), exhibiting a binding affinity (Ki) of 5.7 nM specifically for CB1R. Due to its characteristics, (Rac)-Zevaquenabant holds promise as an investigative tool in liver fibrosis research. | |||
T73326 |
CB2R-IN-3
|
||
CB2R-IN-3 是大麻素 2 型受体 (CB2R) 的一种选择性拮抗剂。CB2R-IN-3 对人 CB2R 具有高亲和力,对 CB1R 具有特异选择性。CB2R-IN-3 可与 CB2R 的激活剂 CB65 联用。CB2R-IN-3 有效上调抗炎细胞因子的表达,下调促炎细胞因子的表达。 |